Follow the Dianthus Therapeutics, Inc. /DE/ share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €6.5bn. The latest transaction was filed on 19 August 2026 (Levée d'options). Among the most active insiders: Savitz Ryan. Every trade is free.
71
Insider Decl.
n/a
Thresholds
€1m
5 ops.
Buy Volume
€30m
37 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Dianthus Therapeutics, Inc. /DE/ Strong Buy (bullish), based on 13 analysts. Average price target: US$137.62.
47Σ signal
Buys €1m€30m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
126,000 shares@ US$8.440.017% mcap5.2% of flowCommon StockSEC:0001669866-26-000010:1
25 of 71 declarations
About Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of autoimmune diseases. It is listed on NASDAQ under the ticker DE.